Neonatal outcomes and congenital malformations in children born after dydrogesterone application in progestin-primed ovarian stimulation protocol for IVF: a retrospective cohort study

References

• Steptoe PC, Edwards RG. Birth after the reimplantation of a human embryo. Lancet. 1978;2(8085):366. doi:10.1016/S0140-6736(78)92957-4
   PubMed Web of Science ®Google Scholar
• Sunderam S, Kissin DM, Crawford SB, et al. Assisted reproductive technology surveillance - United States, 2013. MMWR Surveill Summ. 2015;64(11):1–25. doi:10.15585/mmwr.ss6411a1
   Web of Science ®Google Scholar
• Yang X, Li Y, Li C, Zhang W. Current overview of pregnancy complications and live-birth outcome of assisted reproductive technology in mainland China. Fertil Steril. 2014;101(2):385–391. doi:10.1016/j.fertnstert.2013.10.01724269043
   PubMed Web of Science ®Google Scholar
• Qin JB, Sheng XQ, Wu D, et al. Worldwide prevalence of adverse pregnancy outcomes among singleton pregnancies after in vitro fertilization/intracytoplasmic sperm injection: a systematic review and meta-analysis. Arch Gynecol Obstet. 2017;295(2):285–301. doi:10.1007/s00404-016-4250-327896474
   PubMed Web of Science ®Google Scholar
• Qin JB, Sheng XQ, Wang H, et al. Worldwide prevalence of adverse pregnancy outcomes associated with in vitro fertilization/intracytoplasmic sperm injection among multiple births: a systematic review and meta-analysis based on cohort studies. Arch Gynecol Obstet. 2017;295(3):577–597. doi:10.1007/s00404-017-4291-228168654
   PubMed Web of Science ®Google Scholar
• Pinborg A, Wennerholm UB, Romundstad LB, et al. Why do singletons conceived after assisted reproduction technology have adverse perinatal outcome? Systematic review and meta-analysis. Hum Reprod Update. 2013;19(2):87–104. doi:10.1093/humupd/dms04423154145
   PubMed Web of Science ®Google Scholar
• Sunkara SK, La Marca A, Seed PT, Khalaf Y. Increased risk of preterm birth and low birthweight with very high number of oocytes following IVF: an analysis of 65 868 singleton live birth outcomes. Hum Reprod. 2015;30(6):1473–1480. doi:10.1093/humrep/dev07625883033
   PubMed Web of Science ®Google Scholar
• Vergouw CG, Kostelijk EH, Doejaaren E, Hompes PG, Lambalk CB, Schats R. The influence of the type of embryo culture medium on neonatal birthweight after single embryo transfer in IVF. Hum Reprod. 2012;27(9):2619–2626. doi:10.1093/humrep/des25222791752
   PubMed Web of Science ®Google Scholar
• Alviggi C, Conforti A, Carbone IF, Borrelli R, de Placido G, Guerriero S. Influence of cryopreservation on perinatal outcome after blastocyst- vs cleavage-stage embryo transfer: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2018;51(1):54–63. doi:10.1002/uog.1894229077229
   PubMed Web of Science ®Google Scholar
• Anthony S, Buitendijk SE, Dorrepaal CA, Lindner K, Braat DD, Den Ouden AL. Congenital malformations in 4224 children conceived after IVF. Hum Reprod. 2002;17(8):2089–2095. doi:10.1093/humrep/17.8.208912151442
   PubMed Web of Science ®Google Scholar
• Bonduelle M, Oberye J, Mannaerts B, Devroey P. Large prospective, pregnancy and infant follow-up trial assures the health of 1000 fetuses conceived after treatment with the GnRH antagonist ganirelix during controlled ovarian stimulation. Hum Reprod. 2010;25(6):1433–1440. doi:10.1093/humrep/deq07220378616
   PubMed Web of Science ®Google Scholar
• Bosch E, Valencia I, Escudero E, et al. Premature luteinization during gonadotropin-releasing hormone antagonist cycles and its relationship with in vitro fertilization outcome. Fertil Steril. 2003;80(6):1444–1449. doi:10.1016/j.fertnstert.2003.07.00214667881
   PubMed Web of Science ®Google Scholar
• Reichman DE, Zakarin L, Chao K, Meyer L, Davis OK, Rosenwaks Z. Diminished ovarian reserve is the predominant risk factor for gonadotropin-releasing hormone antagonist failure resulting in breakthrough luteinizing hormone surges in in vitro fertilization cycles. Fertil Steril. 2014;102(1):99–102. doi:10.1016/j.fertnstert.2014.07.124324882557
   PubMed Web of Science ®Google Scholar
• Kuang Y, Chen Q, Fu Y, et al. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril. 2015;104(1):62–70.e63. doi:10.1016/j.fertnstert.2015.03.02225956370
   PubMed Web of Science ®Google Scholar
• Lu X, Hong Q, Sun L, et al. Dual trigger for final oocyte maturation improves the oocyte retrieval rate of suboptimal responders to gonadotropin-releasing hormone agonist. Fertil Steril. 2016;106(6):1356–1362. doi:10.1016/j.fertnstert.2016.07.106827490046
   PubMed Web of Science ®Google Scholar
• Zhang J, Mao X, Wang Y, et al. Neonatal outcomes and congenital malformations in children born after human menopausal gonadotropin and medroxyprogesterone acetate treatment cycles. Arch Gynecol Obstet. 2017;296(6):1207–1217. doi:10.1007/s00404-017-4435-428948397
   PubMed Web of Science ®Google Scholar
• Wang N, Lin J, Zhu Q, et al. Comparison of neonatal outcomes and live-birth defects after progestin-primed ovarian stimulation versus conventional ovarian stimulation for in vitro fertilization: a large retrospective cohort study. Medicine (Baltimore). 2018;97(34):e11906. doi:10.1097/MD.000000000001190630142796
   PubMed Web of Science ®Google Scholar
• Rizner TL, Brozic P, Doucette C, et al. Selectivity and potency of the retroprogesterone dydrogesterone in vitro. Steroids. 2011;76(6):607–615. doi:10.1016/j.steroids.2011.02.04321376746
   PubMed Web of Science ®Google Scholar
• Griesinger G, Tournaye H, Macklon N, et al. Dydrogesterone: pharmacological profile and mechanism of action as luteal phase support in assisted reproduction. Reprod Biomed Online. 2019;38(2):249–259. doi:10.1016/j.rbmo.2018.11.01730595525
   PubMed Web of Science ®Google Scholar
• Yu S, Long H, Chang HY, et al. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Hum Reprod. 2018;33(2):229–237. doi:10.1093/humrep/dex36729300975
   PubMed Web of Science ®Google Scholar
• Harris BS, Bishop KC, Kemeny HR, Walker JS, Rhee E, Kuller JA. Risk factors for birth defects. Obstet Gynecol Surv. 2017;72(2):123–135. doi:10.1097/OGX.000000000000044228218773
   PubMed Web of Science ®Google Scholar
• Kamath MS, Antonisamy B, Selliah HY, La Marca A, Sunkara SK. Perinatal outcomes following IVF with use of donor versus partner sperm. Reprod Biomed Online. 2018;36(6):705–710. doi:10.1016/j.rbmo.2018.03.01629673729
   PubMed Web of Science ®Google Scholar
• Gerkowicz SA, Crawford SB, Hipp HS, Boulet SL, Kissin DM, Kawwass JF. Assisted reproductive technology with donor sperm: national trends and perinatal outcomes. Am J Obstet Gynecol. 2018;218(4):421.e421–421.e410.
   PubMed Web of Science ®Google Scholar
• Cummins JM, Breen TM, Harrison KL, Shaw JM, Wilson LM, Hennessey JF. A formula for scoring human embryo growth rates in in vitro fertilization: its value in predicting pregnancy and in comparison with visual estimates of embryo quality. J In Vitro Fert Embryo Transf. 1986;3(5):284–295. doi:10.1007/BF01133388
   PubMedGoogle Scholar
• Gardner DK, Schoolcraft WB. In vitro culture of human blastocyst In: Jansen R, Mortimer D, editors. Towards Reproductive Certainty: Infertility and Genetics beyond 1999. Carnforth: Parthenon Press; 1999:378–388.
   Google Scholar
• Chen H, Wang Y, Lyu Q, et al. Comparison of live-birth defects after luteal-phase ovarian stimulation vs. conventional ovarian stimulation for in vitro fertilization and vitrified embryo transfer cycles. Fertil Steril. 2015;103(5):1194–1201.e1192.25813280
   PubMed Web of Science ®Google Scholar
• Dai L, Deng C, Li Y, et al. Birth weight reference percentiles for Chinese. PLoS One. 2014;9(8):e104779. doi:10.1371/journal.pone.010477925127131
   PubMed Web of Science ®Google Scholar
• Dai L, Deng C, Li Y, et al. Population-based birth weight reference percentiles for Chinese twins. Ann Med. 2017;49(6):470–478. doi:10.1080/07853890.2017.129425828276868
   PubMed Web of Science ®Google Scholar
• Krisher RL. The effect of oocyte quality on development. J Anim Sci. 2004;82 E-Suppl:E14–E23.15471793
   PubMedGoogle Scholar
• Silva CC, Knight PG. Effects of androgens, progesterone and their antagonists on the developmental competence of in vitro matured bovine oocytes. J Reprod Fertil. 2000;119(2):261–269.10864838
   PubMedGoogle Scholar
• Zavareh S, Saberivand A, Salehnia M. The effect of progesterone on the in vitro maturation and developmental competence of mouse germinal vesicle oocytes. Int J Fertil Steril. 2009;3(1):21–28.
   Web of Science ®Google Scholar
• Carter F, Rings F, Mamo S, et al. Effect of elevated circulating progesterone concentration on bovine blastocyst development and global transcriptome following endoscopic transfer of in vitro produced embryos to the bovine oviduct. Biol Reprod. 2010;83(5):707–719. doi:10.1095/biolreprod.109.08235420631399
   PubMed Web of Science ®Google Scholar
• Aparicio IM, Garcia-Herreros M, O’Shea LC, Hensey C, Lonergan P, Fair T. Expression, regulation, and function of progesterone receptors in bovine cumulus oocyte complexes during in vitro maturation. Biol Reprod. 2011;84(5):910–921. doi:10.1095/biolreprod.110.08741121228216
   PubMed Web of Science ®Google Scholar
• Yamashita Y, Shimada M, Okazaki T, Maeda T, Terada T. Production of progesterone from de novo-synthesized cholesterol in cumulus cells and its physiological role during meiotic resumption of porcine oocytes. Biol Reprod. 2003;68(4):1193–1198. doi:10.1095/biolreprod.102.01093412606468
   PubMed Web of Science ®Google Scholar
• Bosch E, Labarta E, Crespo J, et al. Circulating progesterone levels and ongoing pregnancy rates in controlled ovarian stimulation cycles for in vitro fertilization: analysis of over 4000 cycles. Hum Reprod. 2010;25(8):2092–2100. doi:10.1093/humrep/deq12520539042
   PubMed Web of Science ®Google Scholar
• Venetis CA, Kolibianakis EM, Bosdou JK, Tarlatzis BC. Progesterone elevation and probability of pregnancy after IVF: a systematic review and meta-analysis of over 60 000 cycles. Hum Reprod Update. 2013;19(5):433–457. doi:10.1093/humupd/dmt01423827986
   PubMed Web of Science ®Google Scholar
• Zhang L, Chen J, Wang Y, Ren F, Yu W, Cheng L. Pregnancy outcome after levonorgestrel-only emergency contraception failure: a prospective cohort study. Hum Reprod. 2009;24(7):1605–1611. doi:10.1093/humrep/dep07619336440
   PubMed Web of Science ®Google Scholar
• Kuang Y, Hong Q, Chen Q, et al. Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection treatment, with optimal pregnancy outcomes in frozen-thawed embryo transfer cycles. Fertil Steril. 2014;101(1):105–111. doi:10.1016/j.fertnstert.2013.09.00724161646
   PubMed Web of Science ®Google Scholar
• Zhu X, Zhang X, Fu Y. Utrogestan as an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Medicine (Baltimore). 2015;94(21):e909. doi:10.1097/MD.000000000000087426020402
   PubMed Web of Science ®Google Scholar
• Zhu X, Ye H, Fu Y. Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic sperm injection treatments in combination with embryo cryopreservation. Fertil Steril. 2017;108(3):505–512.e502.28697910
   PubMed Web of Science ®Google Scholar
• Zaqout M, Aslem E, Abuqamar M, Abughazza O, Panzer J, De Wolf D. The impact of oral intake of dydrogesterone on fetal heart development during early pregnancy. Pediatr Cardiol. 2015;36(7):1483–1488. doi:10.1007/s00246-015-1190-925972284
   PubMed Web of Science ®Google Scholar
• Tournaye H, Sukhikh GT, Kahler E, Griesinger G, Phase A. III randomized controlled trial comparing the efficacy, safety and tolerability of oral dydrogesterone versus micronized vaginal progesterone for luteal support in in vitro fertilization. Hum Reprod. 2017;32(5):1019–1027. doi:10.1093/humrep/dex02328333318
   PubMed Web of Science ®Google Scholar
• Griesinger G, Blockeel C, Sukhikh GT, et al. Oral dydrogesterone versus intravaginal micronized progesterone gel for luteal phase support in IVF: a randomized clinical trial. Hum Reprod. 2018;33(12):2212–2221.30304457
   PubMed Web of Science ®Google Scholar
• Yu HT, Yang Q, Sun XX, et al. Association of birth defects with the mode of assisted reproductive technology in a Chinese data-linkage cohort. Fertil Steril. 2018;109(5):849–856. doi:10.1016/j.fertnstert.2018.01.01229778384
   PubMed Web of Science ®Google Scholar
• Blockeel C, Drakopoulos P, Santos-Ribeiro S, Polyzos NP, Tournaye H. A fresh look at the freeze-all protocol: a SWOT analysis. Hum Reprod. 2016;31(3):491–497.26724793
   PubMed Web of Science ®Google Scholar